UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
"We are very pleased to enter a collaboration with UNION.
- "We are very pleased to enter a collaboration with UNION.
- This collaboration further strengthens our position in autoimmune by adding a mid-stage potential best-in-class therapy into our portfolio.
- Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.
- The company is currently working with two complementary chemistry classes, spanning immunology and microbiology with seven programs in clinical development.